


# Smart Contact Lenses Market to reach USD 10.72 Million by 2035 at 6.85% CAGR

*Smart Contact Lenses Market to Grow from USD 5.91M in 2026 to USD 10.72M by 2035—Driven by Sub-Microwatt Biosensor Miniaturization, Reimbursement Code Expansion*

NY, CA, UNITED STATES, June 30, 2026 /EINPresswire.com/ -- As per Market Research Future, the [global Smart Contact Lenses Market size](#) is projected to reach USD 10.72 Million by 2035 from USD 5.91 Million in 2026, registering a CAGR of 6.85% during the forecast period 2026–2035. The market base was estimated at USD 5.50 Million in 2025.



The 6.85% CAGR—anchored in clinical reimbursement momentum rather than discretionary consumer spending—is driven by three converging forces: sub-microwatt biosensor miniaturization that has made 24-hour continuous lens wear technically viable, reimbursement code expansion that is converting smart lenses from out-of-pocket novelties into covered chronic-disease-management tools, and 5G/LTE-M connectivity integration that has solved the latency problems holding back earlier Bluetooth-only lens architectures.

Regulatory and government bodies are reinforcing this momentum. The US FDA's De Novo classification pathway cleared two IOP-monitoring devices in 2024, while government health agencies across OECD countries have earmarked over USD 420 Million in digital therapeutics funding through 2030 for tear-based diagnostics and connected ocular platforms. Silicon-hydrogel nanocomposite substrates have cut manufacturing reject rates by nearly 30% since 2022, and venture capital flowing into ophthalmic wearables surpassed USD 310 Million cumulatively through 2024. Together, these developments are building the clinical and commercial infrastructure on which the Smart Contact Lenses Market depends.

Request A Free Sample:

[https://www.marketresearchfuture.com/sample\\_request/1186](https://www.marketresearchfuture.com/sample_request/1186)

## Key Market Trends & Growth Drivers

### Sub-Microwatt Biosensor Miniaturization

Power consumption below one microwatt is the inflection point that makes 24-hour continuous wear viable. Stanford's Byers Center for Biodesign demonstrated a 0.3  $\mu\text{W}$  tear-glucose sensor in late 2023 that sustained 18-hour operation on a thin-film supercapacitor harvesting blink energy. This breakthrough has halved the minimum viable sensor footprint from 1.2  $\text{mm}^2$  to 0.6  $\text{mm}^2$ , allowing manufacturers to embed two independent analyte channels—glucose and intraocular pressure—on a single substrate without compromising oxygen permeability. This driver carries an estimated 18% impact on overall CAGR, applying globally on a two-year-or-less timeline.

### Reimbursement Code Expansion

CMS introduced two Category III CPT codes for continuous IOP monitoring via smart lenses in January 2025, covering 90-day monitoring episodes under chronic disease management. Germany's Federal Joint Committee followed with a positive health technology assessment for tear-based glaucoma screening in March 2025. These milestones matter because device adoption in ophthalmology historically tracks reimbursement availability within 18–24 months of code publication, contributing roughly 16% of CAGR impact concentrated in North America and Europe over a two-to-four-year horizon.

### 5G and LTE-M Connectivity Integration

Low-power wide-area network protocols, particularly LTE-M and NB-IoT, solve the latency challenge that hampered earlier Bluetooth-only smart lens architectures. SK Telecom's partnership with a Seoul-based lens developer achieved sub-200 millisecond data transmission from lens to cloud in field trials across three Korean hospitals in 2024. Secure, real-time data feeds into electronic health record platforms strengthen the clinical value proposition that institutional procurement depends on, an effect estimated at roughly 14% of CAGR impact across Asia-Pacific and North America.

Ask for Customization:

[https://www.marketresearchfuture.com/ask\\_for\\_customize/1186](https://www.marketresearchfuture.com/ask_for_customize/1186)

## Market Segment Insights

### BY APPLICATION

Ocular Monitoring & Glaucoma Treatment: Dominant segment with 54.5% revenue share in 2025, reflecting the acute clinical need for continuous IOP tracking among an estimated 80 Million global glaucoma patients. Lens platforms in this segment integrate piezoresistive sensors that detect IOP fluctuations within  $\pm 0.5$  mmHg, feeding alerts to companion smartphone applications, and benefit from the strongest reimbursement tailwinds of any application category.

Vision Impairment: Growing segment at 8.25% CAGR (2026–2035) as electronically adjustable focal-length technology matures. Prototype lenses demonstrated at ARVO 2024 achieved real-time diopter adjustment across a –6.0 to +3.0 range using liquid-crystal optical elements, positioning this as the fastest-growing application category as presbyopia prevalence rises among aging populations.

#### BY END USER

Hospitals & Ophthalmology Clinics: Largest end-user segment with 42.7% share in 2025. Institutional buyers control formulary decisions and possess the technical infrastructure to integrate lens data into existing EHR workflows, anchoring the primary revenue channel for the market.

Home-care/Self-monitoring Consumers: Fastest-growing end-user segment at 8.52% CAGR (2026–2035), fueled by direct-to-patient prescription models and smartphone-based companion platforms that eliminate the need for in-clinic data downloads.

Others (Research Institutions, Military): USD 0.47 Million in 2025, sustained by clinical trial activity and defense R&D funding.

Read Detailed Insights:

<https://www.marketresearchfuture.com/reports/smart-contact-lenses-market-1186>

#### Regional Outlook

North America – Dominant Market (~54.4% Share, 2025)

The United States generates approximately 78.2% of North American Smart Contact Lenses Market revenue, with the NIH allocating USD 48 Million to wearable ocular diagnostics research between 2023 and 2026. CMS reimbursement pilot programs in six states are expected to transition to permanent coverage by 2028, which will catalyze hospital procurement cycles that currently run 12–18 months. Robust insurance pilot programs and dense ophthalmology networks anchor regional leadership.

Canada contributes through provincial digital therapeutics programs at 13.5% of regional share, while Mexico holds 8.3% of regional share on cross-border clinical trial partnerships.

Europe – Second Largest (~23.1% Share, 2025)

Europe's Smart Contact Lenses Market benefits from the EU MDR's Class IIa regulatory framework, which provides a harmonized approval pathway across 27 member states. Germany is growing at 6.92% CAGR on the back of the G-BA's positive HTA assessment and MedTech cluster investment. The UK holds 28.4% of regional share, where the NHS Innovation Accelerator selected two smart lens developers in 2024, accelerating procurement timelines and validating continuous IOP-monitoring use cases.

France contributed USD 0.21 Million through ANSM's expedited review pathways, while Italy contributed USD 0.14 Million on its ophthalmic device manufacturing base. Spain is growing at 6.55% CAGR on its national diabetes prevention strategy, the Nordic countries contributed USD 0.09 Million via digital health interoperability mandates, Russia contributed USD 0.06 Million through import-substitution programs, and the rest of Europe contributed USD 0.11 Million on clinical trial site expansion.

#### Asia-Pacific – Fastest-Growing Region (7.61% CAGR, 2026–2035)

Asia-Pacific's growth is anchored by South Korea's contract development and manufacturing organizations, which handle precision micro-assembly at costs 35–40% below North American equivalents. China holds the largest regional share at 31.5% through its State Council medical device innovation initiative. Japan contributes 26.8% of regional share, where the Ministry of Health, Labour and Welfare expanded coverage for digital ophthalmic diagnostics in April 2025, creating immediate institutional demand across the country's 8,400 ophthalmology clinics.

India is growing at 8.18% CAGR on the National Programme for Prevention of Blindness, South Korea contributed USD 0.15 Million through its CDMO precision assembly capacity, ASEAN markets are growing at 7.45% CAGR on diabetic retinopathy screening scale-up, and the rest of Asia-Pacific contributed USD 0.04 Million via university research partnerships.

#### South America – Emerging Adoption (~62.1% of Regional Revenue from Brazil)

Brazil anchors South America's Smart Contact Lenses Market, with the Unified Health System (SUS) launching a diabetic retinopathy telemedicine initiative in 2024 covering 5,500 municipalities, creating a distribution pathway for smart lens screening tools that could reach 35 Million at-risk patients. Argentina contributes 21.3% of regional share through university hospital clinical trials, while the rest of South America contributed USD 0.03 Million on regional health cooperation agreements.

#### Middle East & Africa – Emerging Opportunity

Saudi Arabia leads the Middle East & Africa region with 33.8% of regional share, having directed over USD 1.2 Billion toward health technology infrastructure under its Vision 2030 initiative, including smart wearable diagnostic platforms. The UAE holds 28.9% of regional share on medical tourism and premium device adoption.

South Africa contributed USD 0.03 Million through National Health Insurance pilot coverage, Egypt contributed USD 0.02 Million via WHO-supported screening programs, and the rest of the region contributed USD 0.02 Million through NGO-led vision care programs.

#### Competitive Landscape and Recent Developments

The Smart Contact Lenses Market exhibits medium concentration, with the top five players accounting for an estimated 38–46% of global revenue. The Herfindahl-Hirschman Index sits in the 800–1,200 range, reflecting a blend of established ophthalmic companies and venture-backed startups competing across biosensing, drug delivery, and vision-correction verticals.

The competitive landscape is stratified between continuous-monitoring pioneers serving the clinical IOP and glucose segments, technology-platform entrants leveraging AI and micro-display expertise, and pharmaceutical-ophthalmic convergence players advancing drug-eluting lens platforms.

#### KEY COMPANIES AND RECENT MILESTONES

Sensimed SA (2024–2025): First-mover in CE-marked continuous IOP monitoring through its SENSIMED Triggerfish platform, commanding an estimated 8–12% of global Smart Contact Lenses Market revenue.

Verily Life Sciences, an Alphabet company (2024–2025): Advances a tear-glucose biosensing platform with deep AI/ML analytics integration tied to Google Health, holding roughly 7–10% of global revenue.

Mojo Vision Inc. (2024–2025): Leading developer of the Mojo Lens AR micro-LED display, positioning the company at the forefront of augmented-reality smart lens prototyping, with an estimated 5–8% of global revenue.

Novartis International AG (2024–2025): Pursuing a pharmaceutical-ophthalmic convergence strategy through its Phase II drug-eluting glaucoma lens program; in September 2024 the company reported a 22% improvement in patient adherence compared to daily eye drops, holding roughly 6–9% of global revenue.

Johnson & Johnson Vision (2024–2025): Leveraging the global distribution scale of its conventional lens portfolio to advance its Connected Acuvue platform R&D, holding an estimated 5–8% of global revenue.

Samsung Electronics Co. (May 2025): Announced plans to produce LEDoS micro-displays in 2027 for smart lenses and AR glasses, building on its smart lens patent portfolio and cross-sector semiconductor technology integration; the company holds roughly 4–7% of global revenue.

Sony Group Corporation (2024–2025): Applies miniaturized electronics expertise from its imaging division to micro-display and power-harvesting intellectual property, holding an estimated 3–5% of global revenue.

Alcon Inc. (2024–2025): Integrating its Precision Optics smart lens program into a broader surgical-diagnostic lens ecosystem, holding roughly 4–6% of global revenue.

InWith Corporation (2024–2025): Holds a patented flexible circuit integration approach for soft smart contact lenses with embedded electronics in hydrogel substrates, commanding an estimated 3–5% of global revenue.

Medella Health Inc. (2024–2025): Advances a diabetes-focused tear-based continuous glucose monitoring lens through its clinical pipeline and Health Canada engagement, holding roughly 2–4% of global revenue.

#### Future Outlook: 2026–2035

By the early 2030s, AI-driven predictive diagnostics will become a core differentiator in the Smart Contact Lenses Market. Machine learning algorithms trained on continuous tear-biomarker streams will enable predictive glaucoma alerts 48–72 hours before IOP spikes become clinically significant, and the WHO projects that AI-augmented ophthalmic screening could prevent 3.6 Million cases of preventable blindness annually by 2032. Lens platforms embedding edge-AI inference chips are positioned to capture disproportionate value during the latter half of the forecast period.

Platform economics and recurring-revenue models will reshape commercial strategy. Device-as-a-service subscription models are emerging, bundling lens hardware, cloud analytics, and clinician dashboards into monthly per-patient fees. This pricing architecture shifts revenue recognition from one-time sales to recurring streams, improving vendor lifetime value by an estimated 3.5x and smoothing adoption curves for price-sensitive end users.

IoT-enabled contact lenses will increasingly integrate into broader connected health ecosystems, linking data from wearable patches, implantable sensors, and electronic health records to create comprehensive patient digital twins. Lenses transmitting tear-fluid data alongside cardiac and metabolic readings will give clinicians unprecedented longitudinal health visibility, reinforcing institutional investment in the category.

Sustainability and circular-design mandates will gain regulatory weight by the end of the decade. EU Ecodesign Regulation proposals extending to medical wearables by 2029 will require manufacturers to demonstrate recyclability of electronic components embedded in disposable lenses. Companies investing early in biodegradable substrate research and take-back logistics will gain regulatory advantage and ESG-aligned procurement preference across European hospital networks, positioning the Smart Contact Lenses Market for a structurally diversified path to its USD 10.72 Million 2035 destination.

Larry Wilson

WantStats Research And Media Pvt. Ltd.

+1 855-661-4441

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[YouTube](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/923302229>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.